A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have five parts. Parts A and B of the study will find out how much PF-08046054/SGN- PDL1V should be given to participants. Part C will use the dose found in Parts A and B to find out how safe PF-08046054/SGN-PDL1V is and if it works to treat solid tumor cancers. In Part D and E, participants will be given PF-08046054/SGN-PDL1V with pembrolizumab to find out how safe this combination is and if it works to treat solid tumor cancers.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznaniem histologicznym lub cytologicznym guz złośliwy z przerzutami lub niemożliwy do usunięcia chirurgicznie (płuca, głowa/szyja, przełyk, pierś)
- •Choroba, która nawróciła lub nie odpowiada na leczenie, lub pacjent nie toleruje lub odmawia standardowego leczenia
- •Badanie wykazujące obecność białka PD-L1 w guzie
- •Stan ogólny pacjenta oceniony na 0 lub 1 punkcie (pacjent sprawny, może wykonywać codzienne czynności)
- •Obecność mierzalnego guza widocznego w badaniach obrazowych
✗ Disqualifies
- •Inny nowotwór złośliwy w ciągu ostatnich 3 lat lub pozostałości poprzedniego nowotworu
- •Aktywne przerzuty do mózgu (pacjenci z wyleczonymi przerzutami mogą uczestniczyć, jeśli są stabilni przez 4 tygodnie)
- •Rozsianie do opon mózgowych
- •Poprzednie leczenie lekami anty-PD-L1
- •Wcześniejsze leczenie lekami zawierającymi monomethyluauristain E (MMAE)
- •Istniejące wcześniej uszkodzenie nerwów stopnia 2. lub wyższego
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- April 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (61)
University of Alabama at Birmingham
Birmingham, United States
University of Alabama at Birmingham, IDS Pharmacy
Birmingham, United States
University of Alabama at Birmingham
Birmingham, United States
University of Alabama at Birmingham
Birmingham, United States
Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, United States
UC Irvine Health - Chao Family Comprehensive Cancer Center
Orange, United States
University of California Davis Comprehensive Cancer Center
Sacramento, United States
University of California, Davis Medical Center
Sacramento, United States
University of Iowa
Iowa City, United States
Karmanos Cancer Institute
Detroit, United States
Karmanos Cancer Institute
Farmington Hills, United States
University Hospitals Cleveland Medical Center
Cleveland, United States
University of Texas Southwestern Medical Center - Simmons Cancer Center
Dallas, United States
UT Southwestern Medical Center - Redbird
Dallas, United States
Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital
Dallas, United States
University of Texas Southwestern Medical Center - William P. Clements, Jr., University Hospital
Dallas, United States
University Of Texas Southwestern Medical Center
Dallas, United States
UT Southwestern - Simmons Cancer Center - Fort Worth
Fort Worth, United States
The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services
Houston, United States
The University of Texas MD Anderson Cancer Center
Houston, United States
UT Southwestern - Simmons Cancer Center - Richardson/Plano
Richardson, United States
NEXT Virginia, LLC
San Antonio, United States
South Texas Accelerated Research Therapeutics, LLC
San Antonio, United States
START Mountain Region
West Valley City, United States
NEXT Virginia
Fairfax, United States
Institut Jules Bordet
Anderlecht, Belgium
University Health Network
Toronto, Canada
University Health Network, Princess Margaret Hospital
Toronto, Canada
McGill University Health Centre
Montreal, Canada
Beijing Friendship Hospital, Capital Medical University
Beijing, China
Beijing Cancer Hospital
Beijing, China
Beijing Friendship Hospital Affiliate of Capital University
Beijing, China
Shanghai East Hospital
Shanghai, China
Hôpital Saint André - CHU Bordeaux
Bordeaux, France
Clinique Ambroise Pare
Neuilly-sur-Seine, France
lnstitut Curie Pharmacy
Paris, France
Institut Curie
Paris, France
Gustave Roussy Institute - Service pharmacie
Villejuif, France
Charite Comprehensive Cancer Center
Berlin, Germany
Charite Universitatsmedizin Berlin
Berlin, Germany
Apotheke-Zytostatika Studien Charite- Universitatsmedizin Berlin Campus Virchow Klinkum
Berlin, Germany
Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative lstituto Europeo di Oncologia
Milan, Italy
Centro Ricerche Cliniche di Verona s.r.l. c/o Policlinico G.B Rossi
Verona, Italy
Azienda Ospedaliera Universitaria Integrata Verona - Policlinico G.B Rossi
Verona, Italy
UOC Oncologia - IRCCS Azienda Ospedaliero Universitaria Bologna
Bologna, Italy
National Cancer Center Hospital East
Kashiwa, Japan
Shizuoka Cancer Center
Nagaizumi-cho, Japan
The Netherlands Cancer Institute
Amsterdam, Netherlands
CETIR Viladomat
Barcelona, Spain
Hospital Duran I Reynals-Institut Català d'Oncologia L'Hospitalet (ICO L'Hospitalet)
Barcelona, Spain
Hospital Quiron Salud Barcelona
Barcelona, Spain
NEXT Oncology Barcelona - IOB - Hospital Quironsalud Barcelona
Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
START Madrid - CIOCC - Hospital Universitario HM Sanchinarro
Madrid, Spain
Diagnostic Centre
London, United Kingdom
The Harley Street Clinic (THSC)
London, United Kingdom
Pharmacy: Royal Marsden Hospital
Sutton, United Kingdom
Royal Marsden Hospital
Sutton, United Kingdom
The Royal Marsden NHS Foundation Trust
London, United Kingdom
Sarah Cannon Research Institute
London, United Kingdom
Radiology
London, United Kingdom
Trial contact
Seagen Pfizer CT.gov Call Center
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.